Document is current
Any future updates will be listed below
-
Authors
Chen, Yucherng https://orcid.org/0000-0002-2755-0147
Katayose, Taeko
Nagaoka, Soshi
Piao, Yongzhe
Yamaguchi, Kensei
Asou, Hiroya
-
Funding
Funding for this research was provided by:
Eli Lilly Japan
- License Information
-
More Information
Article History
Received: 24 November 2020
Accepted: 16 May 2021
First Online: 28 May 2021
Declarations
:
: Yucherng Chen, Taeko Katayose, Soshi Nagaoka, Yongzhe Piao, and Hiroya Asou are employees and minor shareholders of Eli Lilly Japan K.K., Kobe, Japan. Kensei Yamaguchi reports grants and personal fees from Eli Lilly Japan K.K. during the conduct of the study; and grants and personal fees from Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Daiichi-Sankyo Co., Ltd, Ono Pharmaceutical Co., Ltd, and Sanofi; grants from Sumitomo Dainippon Pharma Co., Ltd, Boehringer Ingelheim, Gilead Sciences, Inc., and Yakult Honsha Co., Ltd; and personal fees from Merck Serono Co., Ltd, Takeda Pharmaceutical Co., Ltd, Bristol-Myers Squibb, and Bayer, outside the submitted work.
: As a non-interventional post-marketing study, this work was conducted in compliance with the Good Post-marketing Study Practice in Japan. This article does not contain any interventional studies with human or animal subjects performed by any of the authors.
